Toronto, Ontario / TheNewswire / February 17 2017 - Eyecarrot Innovations Corp (TSX-V: EYC) is pleased to announce that it has been awarded up to $149,990 in funding by the National Research Council of Canada Industrial Research Assistance Program (NRC-IRAP) for the commercialization of the company's Binovi Saccadic Fixator, which will integrate seamlessly with its Binovi(TM) platform (currently in private beta). The Saccadic Fixator was originally created in 1974 by industry pioneer and innovator Harry Wayne, and was the first tool to use the combination of electronics and hardware to train and enhance the Oculomotor Sensory System (OMS). With the acquisition of Wayne Engineering in 2015, Eyecarrot has access to over three thousand (3,000) existing Saccadic Fixator customers globally. The company is excited to bring modern technology advancements to these customers via the Binovi(TM) platform, enabling a world-class patient experience by seamlessly integrating software, hardware, data, and expert knowledge of vision care professionals. Eyecarrot's Binovi Saccadic Fixator is the first of several planned hardware devices that will integrate with its Binovi(TM) cloud-based platform.
"Recent research has confirmed that training of the OMS (Oculomotor Sensory system) plays a vital role in the treatment of various vision-related learning issues, recovery from concussions and other traumatic brain injuries, and the enhancement of vision performance in amateur and professional sports. Advancing our Binovi(TM) platform to include hardware instrumentation, the seamless capture of data and reporting of insightful analytics will contribute to our goal of transforming how OMS performance is diagnosed, exercised and enhanced globally. We are grateful to IRAP for their support in helping us commercialize this innovative leap forward for the industry-standard Saccadic Fixator," said CEO, Adam Cegielski.
The Company has also granted an aggregate of 6,660,000 options to Directors, Officers, Employees, and Consultants, having a three (3) year term and exercisable at a price of $0.25 per share.
Eyecarrot's goal is to power a global, data-driven, expert therapeutic network to transform how human Oculomotor Sensory performance is diagnosed, exercised and enhanced. The company is building BinoviTM, a universal, collaborative care platform that integrates software, hardware, data and the expert knowledge of vision care professionals to help patients on a global scale. Learn more at www.eyecarrot.com
On behalf of the Board of Directors
President | CEO
Telephone: 1.855.416.7158 - 416.943.6271
Forward looking information
Certain statements contained in this news release constitute "forward-looking information" as such term is used in applicable Canadian securities laws. Forward-looking information is based on plans, expectations and estimates of management at the date the information is provided and is subject to certain factors and assumptions, including, that the Company's financial condition and development plans do not change as a result of unforeseen events and that the Company obtains regulatory approval. Forward-looking information is subject to a variety of risks and uncertainties and other factors that could cause plans, estimates and actual results to vary materially from those projected in such forward-looking information. Factors that could cause the forward-looking information in this news release to change or to be inaccurate include, but are not limited to, the risk that any of the assumptions referred to prove not to be valid or reliable, that occurrences such as those referred to above are realized and result in delays, or cessation in planned work, that the Company's financial condition and development plans change, and delays in regulatory approval, as well as the other risks and uncertainties applicable to the Company as set forth in the Company's continuous disclosure filings filed under the Company's profile at www.sedar.com . The Company undertakes no obligation to update these forward-looking statements, other than as required by applicable law.
Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.